A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation
- PMID: 8542950
A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation
Abstract
We have assessed the potential use of the mononuclear cell (MNC) content as the sole assessment of graft quality in 35 patients receiving BEAM (carmustine, etoposide, cytosine arabinoside, melphalan) chemotherapy and autologous peripheral blood progenitor cell (PBPC) transplantation for malignant lymphoma. PBPCs were mobilized with cyclophosphamide and granulocyte colony-stimulating factor (G-CSF), and each patient underwent two (n = 20) or three (n = 15) apheresis procedures. Median cell yields were 5.08 x 10(8) MNC/kg (range 1.59-15.70 x 10(8)) and 73.10 x 10(4) CFU-GM/kg (range 0.09-346.72 x 10(4)). All patients achieved hematologic recovery. Median days to neutrophils > or = 0.1 x 10(9)/L, neutrophils > or = 0.5 x 10(9)/L, and platelets > or = 25 x 10(9)/L were 11 (range 8-15), 13 (range 10-37), and 11 (range 7-41), respectively. A close correlation was observed between the MNC and CFU-GM dose (r = 0.79, p < 0.0001). We have previously defined a minimum threshold CFU-GM dose of 20 x 10(4)/kg for patients undergoing high-dose therapy. This corresponds with an MNC dose of 3 x 10(8)/kg. Comparison of engraftment in patients receiving 3 x 10(8) MNC/kg with those receiving lower doses demonstrated significantly longer times to recovery of neutrophils to > or = 0.5 x 10(9)/L and platelets to > or = 25 x 10(9)/L. All patients receiving an MNC dose of > or = 3 x 10(8)/kg achieved neutrophil and platelet recovery by days 12 and 24, respectively. These preliminary data demonstrate that for patients with lymphoma undergoing PBPC mobilization according to this protocol and treatment with BEAM chemotherapy, assessment of MNC dose alone is sufficient to predict early hematologic recovery. Additional assays such as CFU-GM or CD34+ cell counts may not be necessary if this MNC dose is reinfused.
Similar articles
-
Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.Clin Cancer Res. 1998 Feb;4(2):311-6. Clin Cancer Res. 1998. PMID: 9516916 Clinical Trial.
-
High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.Bone Marrow Transplant. 1996 May;17(5):715-21. Bone Marrow Transplant. 1996. PMID: 8733687 Clinical Trial.
-
High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.Bone Marrow Transplant. 1996 Feb;17(2):149-55. Bone Marrow Transplant. 1996. PMID: 8640159 Clinical Trial.
-
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.Bone Marrow Transplant. 1996 Apr;17(4):503-7. Bone Marrow Transplant. 1996. PMID: 8722346 Review.
-
Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapy.Bone Marrow Transplant. 1995 Jun;15(6):923-7. Bone Marrow Transplant. 1995. PMID: 7581092 Review.
Cited by
-
Hematopoietic stem cells in research and clinical applications: The "CD34 issue".World J Stem Cells. 2010 Apr 26;2(2):18-23. doi: 10.4252/wjsc.v2.i2.18. World J Stem Cells. 2010. PMID: 21607112 Free PMC article.
-
Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.Bone Marrow Transplant. 2025 Jan;60(1):19-27. doi: 10.1038/s41409-024-02431-y. Epub 2024 Oct 7. Bone Marrow Transplant. 2025. PMID: 39375527
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Other Literature Sources
Medical